Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis ; volume:38 ; number:8 ; day:13 ; month:5 ; year:2020 ; pages:897 ; date:8.2020
PharmacoEconomics ; 38, Heft 8 (13.5.2020), 897, 8.2020
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40273-020-00925-3
- URN
-
urn:nbn:de:101:1-2020090823362644129544
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ness, Nils-Henning
- Schriefer, Dirk
- Haase, Rocco
- Ettle, Benjamin
- Ziemssen, Tjalf
- SpringerLink (Online service)
Ähnliche Objekte (12)
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis
Seasonal variation in multiple sclerosis relapse
The Societal Costs of Inflation and Unemployment
The societal costs of inflation and unemployment
Societal costs of sepsis in the Netherlands
Societal costs of fetal alcohol syndrome in Sweden
The societal costs of problem gambling in Sweden
Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease
Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder
Personality disorders: the impact of severity on societal costs
Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials
Cognitive progression independent of relapse activity in different multiple sclerosis phenotypes
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis
Seasonal variation in multiple sclerosis relapse
The Societal Costs of Inflation and Unemployment
The societal costs of inflation and unemployment
Societal costs of sepsis in the Netherlands
Societal costs of fetal alcohol syndrome in Sweden
The societal costs of problem gambling in Sweden
Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease
Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder
Personality disorders: the impact of severity on societal costs
Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials
Cognitive progression independent of relapse activity in different multiple sclerosis phenotypes
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis
Seasonal variation in multiple sclerosis relapse
The Societal Costs of Inflation and Unemployment
The societal costs of inflation and unemployment
Societal costs of sepsis in the Netherlands
Societal costs of fetal alcohol syndrome in Sweden
The societal costs of problem gambling in Sweden
Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease
Real-world healthcare resource utilization, costs, and predictors of relapse among US patients with incident schizophrenia or schizoaffective disorder
Personality disorders: the impact of severity on societal costs
Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials